Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
| ▸ | DRD3 | P35462 | 3/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29934322 | 0.80 | HRH3 (0.47) | HRH3NCF1PRMT6CYP11B2CYP2A13 | |
| SCHEMBL20412699 | 0.80 | DRD2 (0.49) | DRD2DRD4DRD3CYP17A1CYP3A4 | |
| SCHEMBL13466368 | 0.80 | NCF1 (0.47) | HRH3NCF1PRMT6CYP11B2MAPT | |
| SCHEMBL18427235 | 0.80 | HRH3 (0.47) | DRD2DRD4DRD3HRH3NCF1 | |
| SCHEMBL18713007 | 0.80 | DRD2 (0.49) | DRD2DRD4DRD3CYP17A1CYP3A4 | |
| SCHEMBL18390555 | 0.80 | DRD2 (0.49) | DRD2DRD4DRD3CYP17A1CYP3A4 | |
| SCHEMBL465728 | 0.80 | NCF1 (0.47) | HRH3NCF1PRMT6CYP11B2MAPT | |
| SCHEMBL14514820 | 0.80 | MAPT (0.49) | HRH3CYP3A4NCF1PRMT6CYP11B2 | |
| SCHEMBL12241726 | 0.80 | CYP11B2 (0.53) | HRH3NCF1PRMT6CYP11B2CYP2A13 | |
| SCHEMBL4757486 | 0.80 | SIGMAR1 (0.47) | DRD2DRD4DRD3HRH3CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140030223-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8569302-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2475657-B1 | 5-ALKINYLTHIEN-2-YLCARBOXYLIC ACIDS AS INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2013-06-12 | — | — | EP | disclosed |
| EP-2475657-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | Gilead Sciences, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| CN-102471327-A | Inhibitors of flaviviridae viruses | GILEAD SCIENCES INC | 2012-05-23 | — | — | CN | disclosed |
| WO-2011011303-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140030223-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | DRD2 4845/4885DRD4 4600/4885DRD3 4725/4885 |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | DRD2 4845/4885DRD4 4600/4885DRD3 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.